Search research articles
Contact Us
Filters
Showing results (171-180 of 208) with videos related to
Page
of 21
Sort By:
Journal of Translational Medicine
|
September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Journal of Translational Medicine
|
July 20, 2023
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)
Paolo A Ascierto, Antonio Avallone, Carlo Bifulco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
Lancet (London, England)
|
March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B Haas, Judith Manola, Robert G Uzzo, et al.
Cancer Discovery
|
March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma
Cara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
Journal for Immunotherapy of Cancer
|
June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L Topalian, Mario Sznol, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
Oncoimmunology
|
December 15, 2018
Clinical characterization of colitis arising from anti-PD-1 based therapy
Daniel Y Wang, Meghan J Mooradian, DaeWon Kim, et al.
The New England Journal of Medicine
|
February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 208) with videos related to
Sort By:
Page
of 21
Journal of Translational Medicine
|
September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Journal of Translational Medicine
|
July 20, 2023
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)
Paolo A Ascierto, Antonio Avallone, Carlo Bifulco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
Lancet (London, England)
|
March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B Haas, Judith Manola, Robert G Uzzo, et al.
Cancer Discovery
|
March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma
Cara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
Journal for Immunotherapy of Cancer
|
June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L Topalian, Mario Sznol, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
Oncoimmunology
|
December 15, 2018
Clinical characterization of colitis arising from anti-PD-1 based therapy
Daniel Y Wang, Meghan J Mooradian, DaeWon Kim, et al.
The New England Journal of Medicine
|
February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.
Page
of 21